Please assess the completion status of the following clinical trial:

Trial Title: Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged greater than or equal to 18 years at the time of signing informed consent.~* BMI greater than or equal to 30.0 kg/m\^2~* Prediabetes defined as at least one of the following:~  * HbA1c between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as measured by central laboratory at screening.~ * FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by central laboratory at screening.~Exclusion Criteria:~* History of type 1 or type 2 diabetes.~* Treatment with glucose-lowering agent(s) within 90 days before screening.~* HbA1c greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as measured by central laboratory at screening.~* FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory at screening.~A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records.~* Treatment with any medication for the indication of obesity within the past 90 days before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).